Relative Bioavailability Study of HNC364 Injectable Suspension
Phase 1
Not yet recruiting
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Drug: HNC364 Injectable SuspensionDrug: Rasagiline Tablets
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06798519
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
Phase 1
Completed
- Conditions
- IPF
- Interventions
- Drug: HNC1058 Capsules
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05803850
- Locations
- 🇺🇸
Syneos Health, Miami, Florida, United States
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05523570
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: HNC042 for InjectionDrug: Placebo Comparator
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04603989
- Locations
- 🇨🇳
Jiang Yuting, Guangzhou, Guangdong, China
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: HNC664 capsules Single doseDrug: HNC664 placebos Single doseDrug: HNC664 capsules FED
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04504448
- Locations
- 🇺🇸
Pharmaron, Baltimore, Maryland, United States
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Placebo multiple ascending dosesDrug: HNC042 single doseDrug: HNC042 multiple ascending dosesDrug: Placebo single dose
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT03740555
- Locations
- 🇺🇸
Paolo B. DePetrillo, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath